# Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

> **NCT05010772** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 125 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine and Cedazuridine
- **DRUG:** Enasidenib
- **DRUG:** Gilteritinib
- **DRUG:** Ivosidenib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05010772
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010772, "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05010772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*